Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Prostate Cancer Consensus Panel to Script Testing Guidelines for Inherited Disease

November 19th 2019

Although the oncology community has made many advancements in understanding the role of germline mutations in prostate cancer, a pressing need exists for clarity in determining which genes should be included in testing panels and what steps should be taken to counsel patients at risk and their families.

PROfound Data Could Lead to First PARP Inhibitor Approval in mCRPC

November 17th 2019

Alan H. Bryce, MD, discusses encouraging updates and emerging strategies in metastatic prostate cancer treatment.

Dr. Sartor on the VISION Trial in mCRPC

November 16th 2019

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Selecting Among AR-Directed Agents in Nonmetastatic CRPC

November 16th 2019

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Metastatic CSPC: Toxicity Management & Future Treatment

November 14th 2019

The Role of Enzalutamide in Treating Metastatic CSPC

November 14th 2019

The Approval of Apalutamide for Metastatic CSPC

November 14th 2019

The STAMPEDE Trial Long Term Follow-Up Data

November 14th 2019

The Future of Nonmetastatic CRPC Management

November 14th 2019

The Impact of Recently Approved AR-Targeted Therapy

November 14th 2019

The PROSPER and ARAMIS Trials in CRPC

November 14th 2019

The SPARTAN Trial Interim Analysis

November 14th 2019

Apalutamide in Treating Nonmetastatic CRPC

November 14th 2019

New OS Data in Treatment for Nonmetastatic CRPC

November 14th 2019

Dr. Vargas on Toxicity of SBRT Versus Standard Radiation in Prostate Cancer

November 13th 2019

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Researchers Refining Role of Next-Generation Imaging in Prostate Cancer

November 9th 2019

Phillip J. Koo, MD, discusses the use of conventional imaging as well as the next-generation imaging tools that have the potential to change the management of patients with recurrent prostate cancer.

Dr. Oh on Choosing AR-Targeted Therapy Versus Chemotherapy in mHSPC

November 8th 2019

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

Novel Agents Revolutionize Nonmetastatic CRPC Paradigm

November 5th 2019

Alan H. Bryce, MD, discusses how novel agents have impacted the nonmetastatic castration-resistant prostate cancer space.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Dr. Mohler on Guidelines for Recording Family History in Prostate Cancer

October 31st 2019

James Mohler, MD, discusses what information should be included in a family history, based on the updated National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.